Navigation Links
Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
Date:9/14/2009

BALTIMORE, Sept. 14 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the first quarter ended July 31, 2009. Full details of the Company's financial results are available in the Company's Form 10-Q at www.championsbiotechnology.com.

Total revenues for the first quarter of 2010 were $962,000 as compared to $673,000 in the first quarter of 2009, an increase of 43%. This increase was derived from the Company's Personalized Oncology business, which generated revenues of $899,000 for the first quarter of 2010 compared to $616,000 in the comparable quarter of last year. This increase consisted of increases in Personalized Oncology Tumorgraft studies and vaccines, partially offset by a decrease in revenues from physician panels. Preclinical eValuation revenues for three months ended July 31, 2009, and 2008 were $63,000 and $57,000, respectively.

Costs of Personalized Oncology services for the first quarter of 2010 was $634,000 as compared to $226,000 in the first quarter of 2009, an increase of 181%. The cost of Personalized Oncology services increased due to an increase in the number of Tumorgraft studies, which have higher expenses (lower gross margins) than revenues derived from our physician panels. In addition, the Company recognized the costs of a vaccine development study which required additional up front expenses. Cost of Preclinical eValuation services for the three months ended July 31, 2009, and 2008 were $34,000 and $34,000, respectively.

Research and Development expenses for the first
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
2. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
3. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
4. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
5. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
6. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
7. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
8. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
9. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
10. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
11. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...re/ -- The world,s first concept demonstration t...ugh alternative to replace a petrochemically produ...ber with renewable biomass, made their debut in Co...display at a lounge in the common departure area a...December 21, while the other tire will make appear...
(Date:12/2/2009)...swire-FirstCall/ - Oncolytics Biotech Inc. ("Oncol...announced today that in connection with its previo...e exercised in full their over-allotment option an... is comprised of one common share and 0.4 of a com...e of US$3.00 per unit. Each whole common share pur...
(Date:12/2/2009)...s, December 2 Pepscan Holding NV,...ng on protein mimicking,technology for the generat...,has appointed Wim E.M. Mol, Ph.D. as new Chief Ex...sible for all of Pepscans corporate functions and,...the company. He brings to,Pepscan more than 20 yea...
(Date:12/2/2009)... December 2 Gamida Cell announced ...al (animal study) safety and,efficacy of a gene th...,Cornell Medical College and Gamida Cell. The prod...such as Cooley,s Anemia. , Gamida Cell is... vivo,populations of stem/progenitor cells. The c...
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Dutch Biotech Company Pepscan Appoints New CEO 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3
...today,announced the appointment of industry vetera... further bolstering its position as a leader in th...Mr. Bailye, 54, recently retired from his position... Dendrite was acquired by French information,provi...te, a pharmaceutical,sales force automation system...
...HERAL VASCULAR DEVICE MARKET INSIGHTS WEBINAR ... Thursday, June 5, 2008, 11 am US Eastern Ti...s), PRESENTER: Stephanie LaBelle, Analyst from ...e the link below to register or call Shiu-Yik Au a...Research Group presents a complimentary Webinar ou...
...ire-FirstCall/ - Quest PharmaTech Inc. (TSX-V:,QPT...t its 12-patient,Phase I clinical study entitled "...todynamic Therapy of Actinic Keratosis" has met bo...re delighted to have received, for the first time,...in a dermatological application,",said Madi R. Mad...
Other Biology Technology:IntegriChain Appoints John Bailye to Its Board of Directors 2Peripheral Vascular Device Market Insights Webinar 2Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 2Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 3
(Date:12/3/2009)... investment in energy efficient technologies resea...h Council (EPSRC) Chief Executive Dave Delpy belie...ng research has already brought us fuel cells, mar...stment is needed to develop the capabilities of di...ssion targets by 2020 and limit the impact of clim...
(Date:12/2/2009)...ino men have a more difficult time quitting smokin...ture, but acculturation has no affect on Latinas o... are published in Cancer Epidemiology, Biomarkers...ion for Cancer Research. The December issue has a ...ts smoking cessation differently for Latino men an...
(Date:12/2/2009)...cents exposed to cigarette smoking scenes in movie... and this may be part of the acculturation process...new study findings. , "Our study supports an R-r...hts the global implementation of the World Health ...ol, which includes guidelines for countries to res...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Acculturation affects smoking cessation success among Latinos 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hema 6741 1Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hema 6741 2Blood Clot Threat After Surgery Worse Than Thought 62571 1Blood Clot Threat After Surgery Worse Than Thought 62571 2Blood Clot Threat After Surgery Worse Than Thought 62571 3Blood Sugar Intolerance May Predict Postpartum Ills 62567 1Blood Sugar Intolerance May Predict Postpartum Ills 62567 2
...TON, DC -- Sweetpotatoes, often misunderstood and ...saving food crop in developing countries. , Accor...tato.org ), more than 95 percent of the global swe...ere it is the fifth most important food crop. Desp...e potato. Potatoes are tubers (referring to their ...
...ts have identified a new way to breed brassicas, w...esistant to a damaging virus. Their discovery has ... be durable, broad-spectrum and unlikely to be ove...(TuMV) is an economically devastating virus that i...cially brassicas. In research published recently i...
...ama Barkai will receive the Helen and Martin Kimme...v. 5 at the Weizmann Institute. The award is accom...er five years. , Taking a chance on an experiment.... Living cells are, from this angle, great subject... have all sorts of interesting consequences for ma...
Other Biology News:Sweet potato shines as new promise for small enterprise and hunger relief in developing countries 2Sweet potato shines as new promise for small enterprise and hunger relief in developing countries 3Genes identified to protect brassicas from damaging disease 2Weizmann Institute scientists discover: A 'risk distribution law' for evolution 2
Biolase Core Kit from Bioline
...amplification of GC-rich nucleic acids ,The GC-... a proofreading polymerase, powers through templat...h other polymerases and other blends of polymerase...unique GC-RICH Resolution Solution combine to deli...
...nogen: synthetic peptide corresponding to the thir..., conjugated to KLH. The immunizing peptide has 79...form: Solution in phosphate buffered saline, pH 7....d: IHC (p). Titertest values: immunohistochemistr...
CnC (Cn402-05) from European Collection of Cell Cultures (ECACC)
Biology Products: